---
trial_id: 1892
discovery_date: 2022-10-01 16:58:48.400671
date: 2022-10-01 16:58:48.400671
title: "A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS"
summary: |
  <p>EudraCT Number: 2018-001511-73<br />Sponsor Protocol Number: WA40404<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2019-12-23<br />Medical condition: <br />Disease: <br />Population Age: <br />Gender: <br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HU">HU</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/RO">RO</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001511-73'
published_date: NaT
trial_source: 
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2018-001511-73<br />Sponsor Protocol Number: WA40404<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2019-12-23<br />Medical condition: <br />Disease: <br />Population Age: <br />Gender: <br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/GB">GB</a> (GB - no longer in EU/EEA), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PT">PT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/BE">BE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HU">HU</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/HR">HR</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001511-73/RO">RO</a> (Ongoing)</p>